Viking Therapeutics Inc (VKTX · NASDAQ)
VKTX · MARKET VIEW
Market view · as of Oct 5, 2026
Price (last ~year)
Viking Therapeutics, a clinical-stage biotech focused on metabolic and endocrine disorders, closed a $575.0 million stock and convertible-note offering on September 28, 2026 to fund its VK2735 and VK3019 pipeline, a raise that has diluted the stock — shares are down 27.2% over three months to $29.94, sitting 28.9% below their 52-week high. The company remains pre-revenue with a $125.8M cash position against a $125.2M quarterly operating cash burn (Q2 2026 net loss of $128.0M) and minimal debt of $4.1M. Positive VK2735 weight-maintenance data drove a 36% single-day surge in late September, though the stock has since given back much of that gain, and the company has beaten earnings estimates in just one of the last four quarters.
Valuation
- Market cap
- $3.76B
- PEG
- -0.03
- P/B
- 11.9
- EV/EBITDA
- -71.64
- Beta
- 0.679
- Analyst target
- $94.82
Quality & returns
- Operating margin
- 0.0%
- Profit margin
- 0.0%
- ROE
- -88.8%
- ROA
- -51.9%
Price movement
- Last
- $29.94
- 1-month
- -11.9%
- 3-month
- -27.2%
- RSI (14)
- 47
- vs SMA200
- -9.7%
- 52-wk position
- 23.0% -28.9% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $0 | $-132.6M | $-128.0M | $-127.9M |
| 2026-03-31 | $0 | $-164.1M | $-158.3M | $-158.3M |
| 2025-12-31 | $0 | $-164.7M | $-157.7M | $-157.6M |
| 2025-09-30 | $0 | $-98.6M | $-90.8M | $-90.7M |
Recent news
- Neutral Viking Therapeutics stock faces dilution after USD 575.0 million raise · 2026-10-04
- Bullish VKTX - Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis · 2026-10-03
- Somewhat-Bullish Weight Loss Maintenance Data Could Be A Big Test For Viking Therapeutics Stock (VKTX) · 2026-10-03
- Somewhat-Bullish Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts · 2026-09-30
- Somewhat-Bullish Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. · 2026-09-30
- Somewhat-Bullish VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks · 2026-09-29
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)